Patrick Kock
Overview
Explore the profile of Patrick Kock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
38
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kock P, Badek A, Meyer M, Klaassen A, Walter M, Kindler J
Child Adolesc Psychiatry Ment Health
. 2024 Dec;
18(1):158.
PMID: 39696457
Background: Cannabinoids have been of increasing interest mainly due to their putative efficacy in a wide array of psychiatric, psychosomatic, and neurological conditions. Aims: This systematic review aims to synthesize...
2.
Killer A, Kock P, Klar J, Lerch S, Koenig J, Cavelti M, et al.
Psychopathology
. 2024 Nov;
:1-8.
PMID: 39557034
Background: Differences in subjective stress perception and acute response of the hypothalamic-pituitary-adrenal axis have been reported in internet gaming disorder (IGD). The present study aimed to further investigate alterations in...
3.
Liebrand M, Rebsamen M, Nakamura-Utsunomiya A, von den Driesch L, Kock P, Caccia J, et al.
Front Psychiatry
. 2023 Aug;
14:1206226.
PMID: 37539324
This is the first description of a patient in which adipsic hypernatremia, a rare autoimmune encephalitis, presented in combination with complex psychiatric symptomatology, including psychosis and catatonia. Adipsic hypernatremia is...
4.
Krausz M, Westenberg J, Tsang V, Suen J, Ignaszewski M, Mathew N, et al.
Medicina (Kaunas)
. 2022 Apr;
58(4).
PMID: 35454376
: Now more than ever, there is an obvious need to reduce the overall burden of disease and risk of premature mortality that are associated with mental health and substance...
5.
Kock P, Meyer M, Elsner J, Dursteler K, Vogel M, Walter M
Front Psychiatry
. 2022 Mar;
13:827658.
PMID: 35280170
Adolescence and emerging adulthood are often referred to as youth. Transitional psychiatry addresses this target group, which considers patients between 15 and 25 years of age. Substance use usually begins...
6.
Kock P, Froelich K, Walter M, Lang U, Dursteler K
J Subst Abuse Treat
. 2022 Jan;
138:108717.
PMID: 35012793
Background: Iboga and its primary alkaloids, ibogaine and noribogaine, have been of interest to researchers and practitioners, mainly due to their putative efficacy in treating substance use disorders (SUDs). For...
7.
Meyer M, Strasser J, Kock P, Walter M, Vogel M, Dursteler K
Int J Drug Policy
. 2021 Dec;
101:103548.
PMID: 34920218
Heroin-assisted treatment comprises the use of diacetylmorphine (pharmaceutical heroin) for individuals with severe opioid use disorder. In Switzerland, take-home doses in heroin-assisted treatment are more strictly regulated as compared to...
8.
Kock P, Lang E, Trulley V, Dechent F, Mercer-Chalmers-Bender K, Frei P, et al.
Front Psychiatry
. 2021 Nov;
12:736822.
PMID: 34803760
Psychotic disorders are associated with high rates of comorbid substance use disorders. Use of cannabis rich in tetrahydrocannabinol (THC) is linked to an increased risk of psychosis, worsening of psychotic...
9.
Meyer M, Walter M, Borgwardt S, Scheidegger A, Lang E, Kock P
Front Psychiatry
. 2021 Aug;
12:712110.
PMID: 34366942
The treatment of patients with schizophrenia and substance use disorder poses a challenge for clinicians. Continued use of cannabis and cocaine can exacerbate psychotic symptoms and worsen the course of...
10.
Vogel M, Kock P, Strasser J, Kalbermatten C, Binder H, Dursteler K, et al.
Eur Addict Res
. 2021 Jul;
28(1):80-86.
PMID: 34311466
Introduction: Opioid agonist treatment (OAT) is the first-line treatment for opioid dependence. Currently available OAT options comprise oral (methadone and morphine) and sublingual (buprenorphine) routes of administration. In Switzerland and...